This week on the podcast, we have a conversation with Tim Tinnel, executive vice president/chief operating officer of Intelliguard, talking about – among other things – the looming Drug Supply Chain Security Act (DSCSA) deadline, and Jorge Jorge Santos da Silva, founder and CEO of MoonLake Immunotherapeutics, about its Nanobody programme.Interview times: 01:42 MoonLake Immunotherapeutics 25:24 IntelliguardMoonLake ImmunotherapeuticsLater this year, <a target="_blank" href="https://www.moonlaketx.com/">MoonLake Immunotherapeutics</a> will be announcing its hotly anticipated phase 3 results for its Nanobody sonelokimab for the skin condition hidradenitis suppurativa. The company is looking to sonelokimab to become the first blockbuster Nanobody on the market.MoonLake Immunotherapeutics is a clinical-stage biopharma company unlocking the potential of sonelokimab, a novel investigational Nanobody for the treatment of inflammatory disease. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options.MoonLake was founded in 2021 and is headquartered in Zug, Switzerland.On the podcast this week, we have a conversation with Jorge Santos da Silva, founder and CEO of MoonLake Immunotherapeutics.IntelliguardAs the May 27 DSCSA enforcement deadline approaches, pharmaceutical manufacturers face mounting pressure to meet stringent compliance requirements. The FDA's evolving regulatory landscape presents challenges that can delay drug approvals, disrupt supply chains, and impact patient access to life-saving medications.<a target="_blank" href="https://intelliguardhealth.com/">Intelliguard</a> is at the forefront of helping pharmaceutical companies navigate these complexities. In-house experts specialize in DSCSA compliance, track-and-trace solutions, and regulatory risk mitigation, ensuring companies stay ahead of evolving FDA requirements.Intelliguard is a healthcare technology company dedicated to helping hospitals and health systems focus on patient-centred care. It helps improve operational efficiency, compliance, and clinical decision-making. Its AI-powered Mira Ecosystem integrates RFID automation, real-time visibility, and predictive analytics into a single, unified platform. The company works with more than 700 hospitals across the US.On the podcast this week, we have a conversation with Tim Tinnel, Intelliguard’s executive vice president/chief operating officer.To get in touch with guest suggestions, please email <a target="_blank" href="mailto:jim@deeptechdigest.com">jim@deeptechdigest.com</a>

Base to Base biotech podcast 7: The DSCSA deadline and MoonLake's Nanobody